DiscoveryProbe™ FDA-approved Drug Library: Atomic-Scale Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) from APExBIO comprises 2,320 bioactive compounds approved by leading regulatory agencies, including the FDA, EMA, CFDA, and PMDA (product page). All compounds are pre-dissolved at 10 mM in DMSO, stable for up to 12 months at -20°C and up to 24 months at -80°C. The collection supports both high-throughput (HTS) and high-content screening (HCS), facilitating drug repositioning and pharmacological target identification in cancer, neurodegenerative, and rare disease research (Guo et al., 2022). The library's regulatory breadth ensures clinical relevance and translational value. Robust documentation and standardized formats enable seamless integration into LC-MS and automated screening workflows.

Biological Rationale

Drug repositioning accelerates therapeutic development by repurposing existing, clinically characterized compounds for new indications. This approach reduces development risk and cost compared to de novo drug discovery (see prior article: streamlined screening). The DiscoveryProbe™ FDA-approved Drug Library provides a curated, regulatory-approved set of compounds with well-documented mechanisms, enabling focused screening for target engagement and phenotypic modulation. The collection's inclusion of receptor agonists, antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators addresses diverse pathways implicated in oncology, neurodegeneration, infectious disease, and metabolic disorders. Clinically validated drugs such as doxorubicin (antineoplastic), metformin (antidiabetic), and atorvastatin (lipid-lowering) are representative, ensuring broad biological relevance. Use of such libraries in high-content and high-throughput screening improves the efficiency and translational fidelity of preclinical discovery pipelines.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds with diverse mechanisms of action:

• Receptor Modulation: Agonists and antagonists targeting adrenergic, dopaminergic, serotonergic, and other receptor classes.
• Enzyme Inhibition: Small-molecule inhibitors of kinases, phosphatases, proteases, and metabolic enzymes.
• Ion Channel Regulation: Blockers and modulators of sodium, potassium, calcium, and chloride channels.
• Signal Pathway Regulation: Modulators of pathways such as PI3K/AKT, MAPK, and glycosaminoglycan metabolism (see rare disease focus).

Each compound is supplied at 10 mM in DMSO, enabling direct compatibility with cell-based and biochemical assays. The library's design supports both targeted and phenotypic screening strategies, facilitating the identification of mechanism-specific effects and off-target interactions (for strategic guidance).

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library includes 2,320 unique, clinically approved compounds, covering approvals by FDA, EMA, HMA, CFDA, and PMDA (APExBIO).
• Compounds are pre-dissolved at 10 mM in DMSO and are stable for 12 months at -20°C and 24 months at -80°C (product specification).
• Validated for high-throughput screening (HTS) and high-content screening (HCS) using LC-MS-based workflows, enabling detection of low-abundance features and improved chemical coverage (Guo et al., 2022, DOI).
• JPA joint feature extraction methods increase detection sensitivity by up to 2.3-fold over conventional peak picking in complex mixtures, supporting comprehensive library screening (Guo et al., 2022, DOI).
• Screening enables rapid identification of known and novel pharmacological targets, demonstrated in oncology, neurodegeneration, and infectious disease models (atomic-scale evaluation).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for applications including:

• Drug repositioning and target identification in cancer, neurodegenerative, and rare disease research.
• Mechanistic pathway interrogation in cell-based, biochemical, and organoid assays.
• Validation of LC-MS-based metabolomics and exposomics workflows, leveraging enhanced feature extraction (Guo et al., 2022).
• Pharmacokinetic and pharmacodynamic profiling in preclinical models.

Common Pitfalls or Misconceptions

• Not suitable for primary screening of uncharacterized chemical space: All compounds are clinically approved or pharmacopeia-listed; novel, unapproved scaffolds are not included.
• Does not replace disease-specific custom libraries: Some rare or highly specialized targets may require supplemental compound sourcing.
• In vitro potency may not translate in vivo: Pharmacokinetic profiles and bioavailability vary by indication and species.
• Compounds are dissolved in DMSO: DMSO-sensitive assays may require alternate handling or reformulation.
• Library is not a substitute for regulatory guidance: Clinical translation requires dedicated regulatory assessment beyond screening results.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is available in 96-well and deep well microplates, as well as 2D barcoded screw-top tubes, supporting compatibility with automated liquid handling systems. Each compound is supplied at 10 mM in DMSO, with recommended storage at -20°C or -80°C; stability is 12 months at -20°C and 24 months at -80°C. Shipping is performed on blue ice for evaluation samples and at room temperature or blue ice for larger formats. Key workflow integration steps:

1. Thaw at room temperature; avoid multiple freeze-thaw cycles.
2. Transfer aliquots using multichannel pipettes or automated dispensers.
3. Compatible with LC-MS, HCS, and HTS platforms including robotics and automated imaging systems.
4. Use in concentrations ranging from nanomolar to micromolar, as validated per assay type.
5. Data analysis workflows can leverage advanced feature extraction algorithms (e.g., JPA) to maximize detection and annotation (Guo et al., 2022, DOI).

This article expands upon previous coverage by providing atomic-level parameterization, explicit stability and handling guidance, and detailed mechanistic mapping beyond the scope of earlier translational articles.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO is a rigorously curated, regulatory-compliant compound set that enables atomic-scale drug repositioning and pharmacological target discovery. Its robust documentation, standardized formats, and proven stability profiles support precise, reproducible screening across biomedical research domains. Integration with advanced LC-MS-based feature extraction workflows further enhances sensitivity and chemical coverage (Guo et al., 2022). Future developments may include expansion to emerging regulatory approvals and integration with AI-driven hit prioritization pipelines. For detailed product specifications and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library product page.